Schmidt-Wolf, I.G., Finke, S., Trojaneck, B., Denkena, A., Lefterova, P., Schwella, N., Heuft, H.G., Prange, G., Korte, M., Takeya, M., et al. (1999) Phase I Clinical Study Applying Autologous Immunological Effector Cells Transfected with the Interleukin-2 Gene in Patients with Metastatic Renal Cancer, Colorectal Cancer and Lymphoma. British Journal of Cancer, 81, 1009-1016.
http://dx.doi.org/10.1038/sj.bjc.6690800

has been cited by the following article:

• TITLE: Autologous Natural Killer Cell/Natural Killer T Cell Immunotherapy of Malignant Diseases

  AUTHORS: Aaron J. Smith, John Oertle, Dino Prato

  KEYWORDS: Cancer, Immunotherapy, Autologous, Natural Killer Cells (NK Cells), Natural Killer T Cell (NKT Cells), Lymphocyte Activated Killer Cells (LAK cells)

  JOURNAL NAME: Open Journal of Medical Microbiology, Vol.4 No.3, September 11, 2014

  ABSTRACT: Adoptive immunotherapy, the therapeutic infusion of ex vivo activated cancer-fighting white blood cells that was pioneered by Dr. Steven Rosenberg over 30 years ago, has become more widespread due to outstanding published research documenting the clinical efficacy of this strategy. Based on the well-established in vivo functions of NK and NKT cells, their integral role in the efficacy of certain chemotherapeutic and immunomodulatory agents, and their direct therapeutic action as displayed in clinical trials, the use of autologous natural killer cell infusions is an appropriate and warranted therapeutic option for the treatment of malignant diseases, especially in patients whose disease is refractory to standard treatments such as chemotherapy and radiation.